MedTrace Logo

A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

NCT05318976 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2026-03-27

No results posted yet for this study

Summary

The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro1595 in patients with early ADi.

Conditions

Interventions

DRUG

XPro1595

XPro1595 will be delivered by subcutaneous injection once a week

DRUG

Placebo

Placebo will be delivered by subcutaneous injection once a week

Sponsors & Collaborators

  • Inmune Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Therese Blomberg · INmune Bio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-28
Primary Completion
2025-05-12
Completion
2025-05-12

Countries

  • Australia
  • Canada
  • Czechia
  • France
  • Germany
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05318976 on ClinicalTrials.gov